tide, which is present in greatest amounts in the central and autonomic nervous systems, has previously been found in bronchial neoplasms. The mean serum concentration of leucine-enkephalin was significantly greater in the patients with carcinoma (1035 pglml) than in the control subjects (426 pgjml). In the 23 patients with a tumour in non-apical regions of the lung, however, the mean concentration of the peptide (422 pglml) did not differ significantly from that in control subjects; serum concentrations in the seven patients with an apical neoplasm (mean 3050 (range 1259-5820) pg/ ml) were significantly greater than values in either the control subjects or the patients with non-apical lung tumours. All seven subjects with an apical tumour had one In all cases venesection was carried out between 07.00 and 11.00 before bronchoscopy and after an overnight fast, before any centrally acting sedative drugs had been given. All subjects had been awake for at least one hour. None of them had been given any previous treatment likely to affect the nervous system or to interfere with serum enkephalin concentrations. In particular, no patients had been treated with opiates for purposes of analgesia and none was taking any other centrally acting drugs.
Owing to the lability of leu-enkephalin and its sensitivity to protein and salt concentrations, all procedures were performed on crushed ice and all sera reconstituted or diluted with peptone-borate buffer containing merthiolate as a preservative. Blood was taken into cooled plain glass tubes packed in ice and Thorax 1990;45:9-1 1 centrifuged at 1700 rev/min at 4°C for 15 minutes before being stored at -80°C until assay. The peptide was measured by a standard radioimmunoassay technique (Incstar Corporation, Minnesota) using iodine-125 labelled leu-enkephalin, anti-leu-enkephalin antibody, and phase separation by saturated ammonium sulphate in the presence of carrier gammaglobulin. Specimens were counted with a Packard Crystal II gamma counter. All samples were assayed in duplicate. Internal quality controls (control sera in which the concentration of leu-enkephalin was known) were included to ensure the validity of results. The sensitivity of the assay system was 100 pg/ml of leu-enkephalin. Cross [617] . When the patients with carcinoma, however, were divided according to the site of their tumour into "apical" and "non-apical" groups, there was a highly significant difference between control subjects and those with a lesion at the apex (p < 0 001), but no significant difference between control subjects and the patients with a non-apical tumour (p = 0A499). The 23 patients with a non-apical tumour had serum values ranging from 218 to 883 pg/ml with a mean of 422 (33) pg/ml [398] ; in the seven patients with apical disease values ranged from 1259 to 5820 pg/ml with a mean of 3050 (648) pg/ml [269] . Three of the seven subjects with apical tumours had all the features of Horner's syndrome (miosis, ptosis, anhidrosis, and enophthalmos); the remaining four had ptosis only. The three patients with the complete syndrome had the three highest serum concentrations of leu-enkephalin-5820, 4687, and 3705 pg/ml (figure).
There was no correlation between histological tumour type and serum concentrations of leu-enkephalin; only two of the seven subjects with an apical tumour had a small cell carcinoma. Of the seven patients with an apical lesion, three had a tumour on the right and four on the left. The Serum leucine-enkephalin in bronchial carcinoma and its relation to tumour location
Immunochemical examination failed to detect leu-enkephalin in the tissue obtained by bronchoscopy from the tumour of any patient. Discussion Bronchial neoplasms, especially those with neuroendocrine differentiation, have a propensity for elaboration and secretion of peptide hormones,7 and leu-enkephalin has been found both within such tumours6 and within neuroendocrine cells in the normal human lung.8 Increased concentrations of this peptide might therefore be expected in the serum of some patients with bronchial carcinoma. Increased concentrations were found in some patients with lung cancer in our study but this was related to location rather than tumour type. This suggests that the raised concentrations arise from invasion ofautonomic ganglia rich in leu-enkephalin, from which the peptide is presumably released rather than from the neoplasm itself. Absence of detectable leu-enkephalin in tissue taken from the tumour at bronchoscopy supports the suggestion that the tissue is not the direct source of the peptide, although small samples of tissue may be unrepresentative of the tumour and rapid secretion of the peptide may leave the tumour depleted of detectable peptide.
We must also consider the possibility that concentrations of leu-enkephalin are increased because other tissues rich in this substance, such as the central nervous system and adrenal glands, are diseased. Release of leu-enkephalin into the cerebrospinal fluid has been described after cerebral infarction in man9 and depletion of the adrenal medulla of this and other neuropeptides has been found in cats after subarachnoid haemorrhage.'0 Of our seven subjects with an apical lesion and a raised serum concentration of leu-enkephalin, one had metastases in bone and one in liver but none had any evidence, clinically or otherwise, of disease of the central nervous system or adrenals. No subject, irrespective of the site of the neoplasm, had a history of cerebrovascular disease; so we do not believe that release of peptide from these tissues could have been responsible for the raised serum concentrations in our subjects.
We do not know whether the apical tumours were destroying or merely compressing the inferior cervical ganglion and adjacent sympathetic nerves, but destruction of tissue is likely to be required for appreciable amounts of peptide to be released. This This study illustrates the need for circumspection in attributing increased concentrations of substances in the blood of patients with neoplasia to the tumour itself. The strict criteria for establishing a substance as being secreted inappropriately" cannot always be satisfied, and care should be taken to exclude mechanisms such as we describe.
We would like to thank Miss Jill Shaw and Alan Williams for their help in preparing the manuscript. The work was part of a larger study supported by the North West Cancer Research Fund (CR93).
location. carcinoma and its relation to tumour
Serum leucine-enkephalin in bronchial
